View in EDS

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir.

Saved in:
Bibliographic Details
Title: The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir.
Authors: Jochmans D; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium., Liu C; Aligos Therapeutics, Inc., South San Francisco, California, USA., Donckers K; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium., Stoycheva A; Aligos Therapeutics, Inc., South San Francisco, California, USA., Boland S; CISTIM Leuven vzw, Leuven, Belgium., Stevens SK; Aligos Therapeutics, Inc., South San Francisco, California, USA., De Vita C; Aligos Therapeutics, Inc., South San Francisco, California, USA., Vanmechelen B; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Clinical & Epidemiological Virology, Leuven, Belgium., Maes P; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Clinical & Epidemiological Virology, Leuven, Belgium., Trüeb B; Institute of Virology and Immunology, University of Bern, Bern, Switzerland., Ebert N; Institute of Virology and Immunology, University of Bern, Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., Thiel V; Institute of Virology and Immunology, University of Bern, Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., De Jonghe S; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium., Vangeel L; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium., Bardiot D; CISTIM Leuven vzw, Leuven, Belgium., Jekle A; Aligos Therapeutics, Inc., South San Francisco, California, USA., Blatt LM; Aligos Therapeutics, Inc., South San Francisco, California, USA., Beigelman L; Aligos Therapeutics, Inc., South San Francisco, California, USA., Symons JA; Aligos Therapeutics, Inc., South San Francisco, California, USA., Raboisson P; Aligos Belgium BV, Leuven, Belgium., Chaltin P; CISTIM Leuven vzw, Leuven, Belgium.; Centre for Drug Design and Discovery (CD3), KU Leuven, Leuven, Belgium., Marchand A; CISTIM Leuven vzw, Leuven, Belgium., Neyts J; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, Maryland, USA., Deval J; Aligos Therapeutics, Inc., South San Francisco, California, USA., Vandyck K; Aligos Belgium BV, Leuven, Belgium.
Source: MBio [mBio] 2023 Feb 28; Vol. 14 (1), pp. e0281522. Date of Electronic Publication: 2023 Jan 10.
Publication Type: Journal Article
Journal Info: Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 101519231 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2150-7511 (Electronic) NLM ISO Abbreviation: mBio Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36625640
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jochmans+D%22">Jochmans D</searchLink>; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Liu+C%22">Liu C</searchLink>; Aligos Therapeutics, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Donckers+K%22">Donckers K</searchLink>; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Stoycheva+A%22">Stoycheva A</searchLink>; Aligos Therapeutics, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Boland+S%22">Boland S</searchLink>; CISTIM Leuven vzw, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Stevens+SK%22">Stevens SK</searchLink>; Aligos Therapeutics, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22De+Vita+C%22">De Vita C</searchLink>; Aligos Therapeutics, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Vanmechelen+B%22">Vanmechelen B</searchLink>; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Clinical & Epidemiological Virology, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Maes+P%22">Maes P</searchLink>; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Clinical & Epidemiological Virology, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Trüeb+B%22">Trüeb B</searchLink>; Institute of Virology and Immunology, University of Bern, Bern, Switzerland.<br /><searchLink fieldCode="AU" term="%22Ebert+N%22">Ebert N</searchLink>; Institute of Virology and Immunology, University of Bern, Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.<br /><searchLink fieldCode="AU" term="%22Thiel+V%22">Thiel V</searchLink>; Institute of Virology and Immunology, University of Bern, Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.<br /><searchLink fieldCode="AU" term="%22De+Jonghe+S%22">De Jonghe S</searchLink>; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Vangeel+L%22">Vangeel L</searchLink>; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Bardiot+D%22">Bardiot D</searchLink>; CISTIM Leuven vzw, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Jekle+A%22">Jekle A</searchLink>; Aligos Therapeutics, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Blatt+LM%22">Blatt LM</searchLink>; Aligos Therapeutics, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Beigelman+L%22">Beigelman L</searchLink>; Aligos Therapeutics, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Symons+JA%22">Symons JA</searchLink>; Aligos Therapeutics, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Raboisson+P%22">Raboisson P</searchLink>; Aligos Belgium BV, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Chaltin+P%22">Chaltin P</searchLink>; CISTIM Leuven vzw, Leuven, Belgium.; Centre for Drug Design and Discovery (CD3), KU Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Marchand+A%22">Marchand A</searchLink>; CISTIM Leuven vzw, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Neyts+J%22">Neyts J</searchLink>; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Deval+J%22">Deval J</searchLink>; Aligos Therapeutics, Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Vandyck+K%22">Vandyck K</searchLink>; Aligos Belgium BV, Leuven, Belgium.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101519231%22">MBio</searchLink> [mBio] 2023 Feb 28; Vol. 14 (1), pp. e0281522. <i>Date of Electronic Publication: </i>2023 Jan 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+for+Microbiology%22">American Society for Microbiology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101519231 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2150-7511 (Electronic) <i>NLM ISO Abbreviation: </i>mBio <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36625640
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1128/mbio.02815-22
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e0281522
    Titles:
      – TitleFull: The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jochmans D
      – PersonEntity:
          Name:
            NameFull: Liu C
      – PersonEntity:
          Name:
            NameFull: Donckers K
      – PersonEntity:
          Name:
            NameFull: Stoycheva A
      – PersonEntity:
          Name:
            NameFull: Boland S
      – PersonEntity:
          Name:
            NameFull: Stevens SK
      – PersonEntity:
          Name:
            NameFull: De Vita C
      – PersonEntity:
          Name:
            NameFull: Vanmechelen B
      – PersonEntity:
          Name:
            NameFull: Maes P
      – PersonEntity:
          Name:
            NameFull: Trüeb B
      – PersonEntity:
          Name:
            NameFull: Ebert N
      – PersonEntity:
          Name:
            NameFull: Thiel V
      – PersonEntity:
          Name:
            NameFull: De Jonghe S
      – PersonEntity:
          Name:
            NameFull: Vangeel L
      – PersonEntity:
          Name:
            NameFull: Bardiot D
      – PersonEntity:
          Name:
            NameFull: Jekle A
      – PersonEntity:
          Name:
            NameFull: Blatt LM
      – PersonEntity:
          Name:
            NameFull: Beigelman L
      – PersonEntity:
          Name:
            NameFull: Symons JA
      – PersonEntity:
          Name:
            NameFull: Raboisson P
      – PersonEntity:
          Name:
            NameFull: Chaltin P
      – PersonEntity:
          Name:
            NameFull: Marchand A
      – PersonEntity:
          Name:
            NameFull: Neyts J
      – PersonEntity:
          Name:
            NameFull: Deval J
      – PersonEntity:
          Name:
            NameFull: Vandyck K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 02
              Text: 2023 Feb 28
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2150-7511
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: MBio
              Type: main
ResultId 1